GLP-1 Agonists for Lung Function Improvement and Muscle Restoration in COPD

NCT07747805 on ClinicalTrials.gov · last registry update 2026-08-05

A small phase 2 — 30 participants, against a typical 110. Due to report 15 August 2028, alongside 23 other tracked readouts that quarter. Primary outcome, as filed: Change in FEV1. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: NOT_YET_RECRUITING
Phase: P2
Drug: tirzepatide
Mounjaro, Zepbound
Sponsor: The Cleveland Clinic
Sponsor type: Other
Enrollment: 30
Started: 2026-08-28
Primary completion: 2028-08-15 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in FEV1

Conditions studied

COPD · Obesity & Overweight · Sarcopenia

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.